Allogene has beaten earnings in 3 straight quarters, but sub-floor quality driven by cash burn and no moat, value-trap margin and leverage signals, justified elevated short interest, and a rejected, implausible analyst price target all argue for treating the stock's headline upside with skepticism.
Thesis pillars
- Value Trap Margin Leverage→Stable
- Perfect Earnings Beat Streak↓Deteriorating
- Sub Floor Quality Cash Burn→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 12, 2026
Allogene Therapeutics, Inc. (ALLO) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $1.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Elevated put/call ratio: 25.50; Below-average business quality.
Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell therapies for cancer and autoimmune disease, anchored by three core programs: cema-cel for first-line large B-cell lymphoma, ALLO-329 for autoimmune disease, and... Read more
Sell if holding. Engine safety override at $1.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Elevated put/call ratio: 25.50; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 4.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Allogene Therapeutics, Inc.
Latest news
- NEWS Allogene Therapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai Oct 26, 2026 neutral
- NEWS Cellectis Pivots to Gene Editing in Major Overhaul — benzinga Sep 14, 2026 neutral
- NEWS Allogene Therapeutics EVP And CFO Geoffrey Parker To Retire, Effective November 6 — benzinga Sep 2, 2026 negative
- NEWS Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target — benzinga Aug 17, 2026 positive
- NEWS Allogene Therapeutics Files Prospectus For $500M Offering — benzinga Aug 12, 2026 neutral
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelead product candidates (cema-cel, ALLO-316, ALLO-329)10-K Item 1A: 'Our business is highly dependent on the success of our lead product candidates.'
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02MEDIUMPresident and CEO David Chang will depart effective June 30, 2026, replaced by Zachary Roberts, M.D., Ph.D. (currently EVP R&D and CMO) effective July 1, 2026; Roberts also joins the Board as a Class I director. Chang is eligible for severance under the company's Change in Control and Severance Benefit Plan. No disagreement cited.SEC filing →
- 2026-05-13Item 1.02MEDIUMAllogene terminated its December 2020 Exclusive License Agreement with Overland Therapeutics covering allogeneic CAR T therapies (BCMA, CD70, FLT3, DLL3) in Greater China, Taiwan, South Korea, and Singapore, entering a new Shareholders' Agreement with Overland and HH BioPharma Holdings. Allogene had received a $40.0 million upfront payment and $79.0 million in Overland preferred stock under the terminated agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Elevated put/call ratio: 25.50; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $1.21. Score 4.6/10, moderate confidence.
Resistance target: $1.58 (+21.5% upside). Prior stop was $1.21. Stop-loss: $1.21.
Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329); DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $1.30 — ratio 6.9×). Rejected, falling back to technical TP.; Quality below floor (1.8 < 4.0).
Allogene Therapeutics, Inc. trades at a P/E of N/A (forward -2.1). TrendMatrix value score: 5.0/10. Verdict: Sell.
18 analysts cover ALLO with a consensus score of 4.2/5. Average price target: $9.
What does Allogene Therapeutics, Inc. do?Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell...
Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell therapies for cancer and autoimmune disease, anchored by three core programs: cema-cel for first-line large B-cell lymphoma, ALLO-329 for autoimmune disease, and ALLO-316 for renal cell carcinoma. The company has no product revenue, reported a $190.9 million net loss and $2.0 billion accumulated deficit for 2025, and licenses gene-editing technology from Cellectis (TALEN) and Arbor Biotechnologies (CRISPR).